Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.55
BIIB's Cash to Debt is ranked lower than
87% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. BIIB: 0.55 )
Ranked among companies with meaningful Cash to Debt only.
BIIB' s Cash to Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.49 Max: N/A
Current: 0.55
Equity to Asset 0.50
BIIB's Equity to Asset is ranked lower than
72% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BIIB: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
BIIB' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.75 Max: 0.84
Current: 0.5
0.48
0.84
Interest Coverage 33.87
BIIB's Interest Coverage is ranked lower than
72% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BIIB: 33.87 )
Ranked among companies with meaningful Interest Coverage only.
BIIB' s Interest Coverage Range Over the Past 10 Years
Min: 19.25  Med: 51.03 Max: 505.19
Current: 33.87
19.25
505.19
F-Score: 5
Z-Score: 5.99
M-Score: -3.02
WACC vs ROIC
5.60%
33.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 47.11
BIIB's Operating margin (%) is ranked higher than
95% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. BIIB: 47.11 )
Ranked among companies with meaningful Operating margin (%) only.
BIIB' s Operating margin (%) Range Over the Past 10 Years
Min: 16.4  Med: 31.63 Max: 45.44
Current: 47.11
16.4
45.44
Net-margin (%) 33.79
BIIB's Net-margin (%) is ranked higher than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. BIIB: 33.79 )
Ranked among companies with meaningful Net-margin (%) only.
BIIB' s Net-margin (%) Range Over the Past 10 Years
Min: 8.11  Med: 23.31 Max: 32.95
Current: 33.79
8.11
32.95
ROE (%) 33.90
BIIB's ROE (%) is ranked higher than
96% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. BIIB: 33.90 )
Ranked among companies with meaningful ROE (%) only.
BIIB' s ROE (%) Range Over the Past 10 Years
Min: 3.09  Med: 18.97 Max: 35.15
Current: 33.9
3.09
35.15
ROA (%) 19.89
BIIB's ROA (%) is ranked higher than
96% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. BIIB: 19.89 )
Ranked among companies with meaningful ROA (%) only.
BIIB' s ROA (%) Range Over the Past 10 Years
Min: 2.57  Med: 13.24 Max: 22.42
Current: 19.89
2.57
22.42
ROC (Joel Greenblatt) (%) 180.35
BIIB's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. BIIB: 180.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIIB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 34.4  Med: 77.96 Max: 189.7
Current: 180.35
34.4
189.7
Revenue Growth (3Y)(%) 26.50
BIIB's Revenue Growth (3Y)(%) is ranked higher than
79% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. BIIB: 26.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIIB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14  Med: 24.80 Max: 85
Current: 26.5
-14
85
EBITDA Growth (3Y)(%) 35.90
BIIB's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. BIIB: 35.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BIIB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.3  Med: 35.10 Max: 86.4
Current: 35.9
-16.3
86.4
EPS Growth (3Y)(%) 38.70
BIIB's EPS Growth (3Y)(%) is ranked higher than
87% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. BIIB: 38.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIIB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.5  Med: 34.90 Max: 201
Current: 38.7
-65.5
201
» BIIB's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

BIIB Guru Trades in Q2 2015

Andreas Halvorsen 513,444 sh (New)
Vanguard Health Care Fund 1,780,330 sh (+425.02%)
Richard Snow 10,500 sh (+320.00%)
Jim Simons 105,261 sh (+247.40%)
RS Investment Management 29,507 sh (+8.49%)
Ron Baron 9,144 sh (unchged)
John Burbank Sold Out
Stanley Druckenmiller Sold Out
Ray Dalio Sold Out
Steven Cohen Sold Out
Ken Fisher 80,932 sh (-0.16%)
PRIMECAP Management 16,501,541 sh (-0.35%)
Pioneer Investments 18,360 sh (-0.61%)
Murray Stahl 8,333 sh (-1.36%)
Mairs and Power 1,095 sh (-2.23%)
Mario Gabelli 4,797 sh (-2.74%)
Frank Sands 4,732,945 sh (-5.52%)
Jeremy Grantham 251,045 sh (-62.48%)
Paul Tudor Jones 600 sh (-87.70%)
» More
Q3 2015

BIIB Guru Trades in Q3 2015

John Burbank 10,551 sh (New)
Ray Dalio 14,766 sh (New)
Steven Cohen 6,800 sh (New)
Joel Greenblatt 9,410 sh (New)
Richard Snow 45,861 sh (+336.77%)
Vanguard Health Care Fund 3,666,723 sh (+105.96%)
Signature Select Canadian Fund 7,900 sh (+43.64%)
Ken Fisher 112,448 sh (+38.94%)
Ron Baron 11,814 sh (+29.20%)
Mairs and Power 1,095 sh (unchged)
Mario Gabelli 4,797 sh (unchged)
Paul Tudor Jones Sold Out
RS Investment Management Sold Out
Andreas Halvorsen Sold Out
Pioneer Investments Sold Out
PRIMECAP Management 15,843,460 sh (-3.99%)
Murray Stahl 7,713 sh (-7.44%)
Frank Sands 4,121,400 sh (-12.92%)
Jeremy Grantham 179,221 sh (-28.61%)
Jim Simons 34,961 sh (-66.79%)
» More
Q4 2015

BIIB Guru Trades in Q4 2015

John Buckingham 17,389 sh (New)
Jeff Auxier 7,195 sh (New)
Paul Tudor Jones 4,368 sh (New)
First Eagle Investment 193,885 sh (New)
Andreas Halvorsen 368,864 sh (New)
John Paulson 36,200 sh (New)
Steven Cohen 86,700 sh (+1175.00%)
Joel Greenblatt 84,577 sh (+798.80%)
Ray Dalio 25,106 sh (+70.03%)
Vanguard Health Care Fund 3,810,023 sh (+3.91%)
Mario Gabelli 4,805 sh (+0.17%)
Mairs and Power 1,095 sh (unchged)
Samuel Isaly 200,000 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
Murray Stahl 7,705 sh (-0.10%)
PRIMECAP Management 15,810,625 sh (-0.21%)
Ken Fisher 110,475 sh (-1.75%)
Richard Snow 40,290 sh (-12.15%)
Ron Baron 10,240 sh (-13.32%)
Frank Sands 3,367,531 sh (-18.29%)
Jeremy Grantham 98,334 sh (-45.13%)
» More
Q1 2016

BIIB Guru Trades in Q1 2016

Vanguard Health Care Fund 3,810,023 sh (unchged)
Murray Stahl 7,705 sh (unchged)
Samuel Isaly 200,000 sh (unchged)
Ken Fisher 90,405 sh (-18.17%)
» More
» Details

Insider Trades

Latest Guru Trades with BIIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.16
BIIB's P/E(ttm) is ranked higher than
74% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. BIIB: 16.16 )
Ranked among companies with meaningful P/E(ttm) only.
BIIB' s P/E(ttm) Range Over the Past 10 Years
Min: 11.74  Med: 26.90 Max: 467.75
Current: 16.16
11.74
467.75
Forward P/E 13.51
BIIB's Forward P/E is ranked higher than
67% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. BIIB: 13.51 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.16
BIIB's PE(NRI) is ranked higher than
74% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. BIIB: 16.16 )
Ranked among companies with meaningful PE(NRI) only.
BIIB' s PE(NRI) Range Over the Past 10 Years
Min: 11.73  Med: 26.89 Max: 530.11
Current: 16.16
11.73
530.11
Price/Owner Earnings (ttm) 19.93
BIIB's Price/Owner Earnings (ttm) is ranked higher than
71% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. BIIB: 19.93 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BIIB' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.6  Med: 25.01 Max: 87.17
Current: 19.93
9.6
87.17
P/B 5.63
BIIB's P/B is ranked lower than
70% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. BIIB: 5.63 )
Ranked among companies with meaningful P/B only.
BIIB' s P/B Range Over the Past 10 Years
Min: 1.71  Med: 3.70 Max: 9.6
Current: 5.63
1.71
9.6
P/S 5.57
BIIB's P/S is ranked higher than
68% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. BIIB: 5.57 )
Ranked among companies with meaningful P/S only.
BIIB' s P/S Range Over the Past 10 Years
Min: 2.81  Med: 6.06 Max: 11.94
Current: 5.57
2.81
11.94
PFCF 18.42
BIIB's PFCF is ranked higher than
65% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. BIIB: 18.42 )
Ranked among companies with meaningful PFCF only.
BIIB' s PFCF Range Over the Past 10 Years
Min: 10.16  Med: 21.98 Max: 39.29
Current: 18.42
10.16
39.29
POCF 15.32
BIIB's POCF is ranked higher than
66% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. BIIB: 15.32 )
Ranked among companies with meaningful POCF only.
BIIB' s POCF Range Over the Past 10 Years
Min: 7.95  Med: 18.01 Max: 35.29
Current: 15.32
7.95
35.29
EV-to-EBIT 11.75
BIIB's EV-to-EBIT is ranked higher than
68% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. BIIB: 11.75 )
Ranked among companies with meaningful EV-to-EBIT only.
BIIB' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.1  Med: 19.00 Max: 68.3
Current: 11.75
8.1
68.3
EV-to-EBITDA 10.55
BIIB's EV-to-EBITDA is ranked higher than
68% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. BIIB: 10.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.6  Med: 15.10 Max: 27
Current: 10.55
6.6
27
PEG 0.55
BIIB's PEG is ranked higher than
92% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. BIIB: 0.55 )
Ranked among companies with meaningful PEG only.
BIIB' s PEG Range Over the Past 10 Years
Min: 0.34  Med: 1.11 Max: 48.49
Current: 0.55
0.34
48.49
Shiller P/E 40.58
BIIB's Shiller P/E is ranked higher than
61% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. BIIB: 40.58 )
Ranked among companies with meaningful Shiller P/E only.
BIIB' s Shiller P/E Range Over the Past 10 Years
Min: 35.83  Med: 74.02 Max: 119.73
Current: 40.58
35.83
119.73
Current Ratio 2.59
BIIB's Current Ratio is ranked lower than
68% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. BIIB: 2.59 )
Ranked among companies with meaningful Current Ratio only.
BIIB' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 3.32 Max: 17.39
Current: 2.59
0.78
17.39
Quick Ratio 2.25
BIIB's Quick Ratio is ranked lower than
69% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. BIIB: 2.25 )
Ranked among companies with meaningful Quick Ratio only.
BIIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.90 Max: 16.79
Current: 2.25
0.7
16.79
Days Inventory 262.83
BIIB's Days Inventory is ranked lower than
82% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. BIIB: 262.83 )
Ranked among companies with meaningful Days Inventory only.
BIIB' s Days Inventory Range Over the Past 10 Years
Min: 219.47  Med: 238.11 Max: 266.3
Current: 262.83
219.47
266.3
Days Sales Outstanding 46.56
BIIB's Days Sales Outstanding is ranked higher than
67% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. BIIB: 46.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.79  Med: 44.30 Max: 48.61
Current: 46.56
39.79
48.61
Days Payable 79.80
BIIB's Days Payable is ranked higher than
58% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. BIIB: 79.80 )
Ranked among companies with meaningful Days Payable only.
BIIB' s Days Payable Range Over the Past 10 Years
Min: 71.44  Med: 105.99 Max: 148.21
Current: 79.8
71.44
148.21

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 16.96
BIIB's Price/Tangible Book is ranked lower than
87% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. BIIB: 16.96 )
Ranked among companies with meaningful Price/Tangible Book only.
BIIB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.91  Med: 6.15 Max: 25.73
Current: 16.96
0.91
25.73
Price/Projected FCF 1.79
BIIB's Price/Projected FCF is ranked higher than
73% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. BIIB: 1.79 )
Ranked among companies with meaningful Price/Projected FCF only.
BIIB' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 2.13 Max: 25.99
Current: 1.79
0.65
25.99
Price/DCF (Earnings Based) 0.57
BIIB's Price/DCF (Earnings Based) is ranked higher than
94% of the 18 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. BIIB: 0.57 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.91
BIIB's Price/Median PS Value is ranked higher than
51% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. BIIB: 0.91 )
Ranked among companies with meaningful Price/Median PS Value only.
BIIB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.99 Max: 6.96
Current: 0.91
0.23
6.96
Price/Peter Lynch Fair Value 0.65
BIIB's Price/Peter Lynch Fair Value is ranked higher than
88% of the 57 Companies
in the Global Biotechnology industry.

( Industry Median: 1.86 vs. BIIB: 0.65 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BIIB' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.44  Med: 1.41 Max: 20.5
Current: 0.65
0.44
20.5
Price/Graham Number 3.49
BIIB's Price/Graham Number is ranked lower than
65% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. BIIB: 3.49 )
Ranked among companies with meaningful Price/Graham Number only.
BIIB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.5  Med: 3.08 Max: 21.42
Current: 3.49
0.5
21.42
Earnings Yield (Greenblatt) (%) 8.42
BIIB's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. BIIB: 8.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIIB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 5.30 Max: 12.3
Current: 8.42
1.5
12.3
Forward Rate of Return (Yacktman) (%) 33.01
BIIB's Forward Rate of Return (Yacktman) (%) is ranked higher than
81% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 13.93 vs. BIIB: 33.01 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIIB' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -4.6  Med: 25.05 Max: 45.3
Current: 33.01
-4.6
45.3

More Statistics

Revenue(Mil) $10936
EPS $ 16.28
Beta0.53
Short Percentage of Float0.97%
52-Week Range $242.07 - 420.99
Shares Outstanding(Mil)219.05

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 11,386 12,208 13,013
EPS($) 18.28 20.25 22.30
EPS without NRI($) 18.28 20.25 22.30

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG » details
Traded in other countries:BIIB34.Brazil, IDP.Germany, BIIB.Mexico, BIIB.Switzerland, 0R1B.UK,
Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company. It discovers, develops, manufactures and markets therapies for the treatment of autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.
» More Articles for NAS:BIIB

Headlines

Articles On GuruFocus.com
10 Years of Strong Returns: Priceline, Biogen Apr 26 2016 
Alaska Air, Delta and NVR Make the 30-30 Club Apr 15 2016 
Undervalued Stocks With Wide Margin of Safety Apr 14 2016 
John Buckingham Trades in ETFs in 4th Quarter Mar 15 2016 
Widely Undervalued Stocks Trading Below Peter Lynch Value Feb 22 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Jeff Auxier Takes Plunge in Fastenal, a Stock From Watchlist Feb 10 2016 
Jean Hynes Finds Her Pot of Gold Jan 07 2016 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Biogen Among Murray Stahl's Holdings With Growing Earnings Nov 11 2015 

More From Other Websites
Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia May 04 2016
Why Biogen Is Hiving Off Its Hemophilia Business May 04 2016
Biogen to Spin Off Hemophilia Business May 03 2016
[$$] Biogen to Spin Off Hemophilia Unit May 03 2016
These Biopharma Companies Are the World’s Top Shareholder Value Creators May 03 2016
Biogen Inc. -- Moody's: Biogen's hemophilia spin-off is credit negative May 03 2016
Will Biogen's Hemophilia Spinoff Hurt the Company Long Term? May 03 2016
Biogen Is All In On Brains May 03 2016
Einhorn's bet on Yelp; Pfizer posts 20% jump; GM's sales miss May 03 2016
Biogen to spin off hemophilia drugs and focus on core neuro business May 03 2016
Biogen's Hemophilia Spin: Prelude to a Takeover? May 03 2016
Biogen Spinning Off Hemophilia Business As Competition Heats Up May 03 2016
Term Sheet — Tuesday, May 3 May 03 2016
How to Trade 5 Biotech Stocks After a Fall -- Plus Jim Cramer's Take May 03 2016
Biogen Plans To Spin-Off Its Hemophilia Unit As Publicly Traded Firm May 03 2016
Early movers: PFE, BIIB, TAP, CVS, MNK, IMS, CLX, COST & more May 03 2016
Biogen to spin off hemophilia business into public company May 03 2016
Biogen to spin off hemophilia drug business into a public company May 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK